Cargando…

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients

There are contrasting findings regarding the effect of HIV on the pharmacokinetics of first‐line anti‐tubercular drugs (FLATDs) due to a lack of prospective controlled clinical studies, including patients with tuberculosis (TB) and patients with TB living with HIV. This study aims to assess the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nardotto, Glauco Henrique Balthazar, Bollela, Valdes Roberto, Rocha, Adriana, Della Pasqua, Oscar, Lanchote, Vera Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841449/ https://www.ncbi.nlm.nih.gov/pubmed/34670022 http://dx.doi.org/10.1111/cts.13169

Ejemplares similares

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
por: Sibley, Laura, et al.
Publicado: (2022)

A Case of Delusional Disorder With Abuse of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, the First-Line Anti-tuberculosis Therapy Drugs in India
por: Sathiyamoorthi, Sathiyanarayanan, et al.
Publicado: (2023)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Ethambutol and pyrazinamide-induced toxic epidermal necrolysis in an immunocompetent adult with tuberculosis
por: Das, Sibes Kumar, et al.
Publicado: (2012)

Damage of testicular cell macromolecules and reproductive capacity of male rats following co-administration of ethambutol, rifampicin, isoniazid and pyrazinamide
por: Shayakhmetova, Ganna Mykhailivna, et al.
Publicado: (2012)

Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin
por: Cestari, Roberta Natália, et al.
Publicado: (2020)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

A case of thrombocytopenia caused by rifampicin and pyrazinamide
por: Bansal, Rekha, et al.
Publicado: (2013)

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol
por: Nakamura, Kayo, et al.
Publicado: (2023)

Blood Agar Validation for Susceptibility Testing of Isoniazid, Rifampicin, Ethambutol, and Streptomycin to Mycobacterium tuberculosis Isolates
por: Coban, Ahmet Yilmaz
Publicado: (2013)

A high‐throughput LC–MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma
por: Pršo, Kristián, et al.
Publicado: (2022)

A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting
por: Andres, Söenke, et al.
Publicado: (2019)

Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice
por: Lai, Jacqueline Mui Lan, et al.
Publicado: (2019)

Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease
por: Kim, Hyung-Jun, et al.
Publicado: (2019)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
por: Brindle, Richard, et al.
Publicado: (2001)

Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia
por: Tessema, Belay, et al.
Publicado: (2012)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Simultaneous detection of ethambutol and pyrazinamide with IL@CoFe(2)O(4)NPs@MWCNTs fabricated glassy carbon electrode
por: Chokkareddy, Rajasekhar, et al.
Publicado: (2020)

Simultaneous determination of the potent anti-tuberculosis regimen—Pyrazinamide, ethambutol, protionamide, clofazimine in beagle dog plasma using LC–MS/MS method coupled with 96-well format plate
por: Wu, Shengyuan, et al.
Publicado: (2019)

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2017)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
por: Habimana, Dominique Savio, et al.
Publicado: (2021)

Bacterial growth dynamics and pharmacokinetic–pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice
por: Muliaditan, Morris, et al.
Publicado: (2021)

Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis
por: Pouplin, Thomas, et al.
Publicado: (2016)

In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using Mycobacterium tuberculosis isolates
por: Hemvani, Nanda, et al.
Publicado: (2012)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

Clostridium, Bacteroides and Prevotella associates with increased fecal metabolites Trans-4-Hydroxy-L-proline and Genistein in active pulmonary tuberculosis patients during anti-tuberculosis chemotherapy with isoniazid-rifampin-pyrazinamide-ethambutol (HRZE)
por: Meng, Ruijie, et al.
Publicado: (2022)

Agranulocytosis Induced by Ethambutol in a Patient with Pulmonary Tuberculosis
por: Moon, Kyoung Min, et al.
Publicado: (2015)

Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil
por: Feliciano, Cinara Silva, et al.
Publicado: (2019)

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice
por: Almeida, Deepak V., et al.
Publicado: (2014)

Serum pyrazinamide concentrations in patients with pulmonary tuberculosis
por: Lucena, Stefania de Medeiros Araujo, et al.
Publicado: (2019)

Calcitriol enhances pyrazinamide treatment of murine tuberculosis
por: Zhang, Jing, et al.
Publicado: (2019)

HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis
por: Loiseau, Chloé, et al.
Publicado: (2020)

Prevalence of rifampicin resistance tuberculosis among HIV/TB coinfected patients in Benue State, Nigeria
por: Ejeh, Francis Enenche, et al.
Publicado: (2021)

Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide
por: Saifullah, Bullo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_116kmt9cs53k7p4ci9d8ru4dim